(Q38919128)

7 September 2017

title

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia (English)

1 reference

7 September 2017

0 references

1 reference

1 reference

Mohamed Bradai

1

1 reference

7 September 2017

Serge Pissard

2

1 reference

7 September 2017

Mohand Tayeb Abad

3

1 reference

7 September 2017

Agnes Dechartres

4

1 reference

7 September 2017

Jean-Antoine Ribeil

5

1 reference

7 September 2017

Paul Landais

6

1 reference

7 September 2017

Mariane de Montalembert

7

1 reference

7 September 2017

language of work or name

1 reference

1 October 2007

1 reference

7 September 2017

1 reference

7 September 2017

volume

47

1 reference

7 September 2017

issue

10

1 reference

7 September 2017

page(s)

1830-1836

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

7 September 2017

1 reference

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Hydroxyurea therapy in thalassemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Hydroxyurea in thalassemia intermedia--a promising therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Do alpha deletions influence hydroxyurea response in thalassemia intermedia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Is hydroxyurea leukemogenic in children with sickle cell disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

Malignancy in patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01399.X

10.1111/J.1537-2995.2007.01399.X

21 January 2018

Identifiers

DOI

1 reference

release_phye5egszjhphp6vs3q7w35asi

7 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/phye5egszjhphp6vs3q7w35asi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference